T. Rowe Price Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.2M | Buy |
230,996
+53,604
| +30% | +$416K | ﹤0.01% | 1787 |
|
|
2025
Q4 | $1.38M | Buy |
177,392
+16,044
| +10% | +$116K | ﹤0.01% | 1936 |
|
|
2025
Q3 | $1.23M | Buy |
161,348
+14,709
| +10% | +$122K | ﹤0.01% | 1966 |
|
|
2025
Q2 | $1.31M | Buy |
146,639
+12,344
| +9% | +$115K | ﹤0.01% | 1843 |
|
|
2025
Q1 | $1.01M | Buy |
134,295
+7,489
| +6% | +$60.4K | ﹤0.01% | 1955 |
|
|
2024
Q4 | $954K | Sell |
126,806
-2,125,943
| -94% | -$16.1M | ﹤0.01% | 1991 |
|
|
2024
Q3 | $17.1M | Buy |
2,252,749
+303,765
| +16% | +$2.31M | ﹤0.01% | 1026 |
|
|
2024
Q2 | $12M | Buy |
1,948,984
+1,818,209
| +1,390% | +$10M | ﹤0.01% | 1076 |
|
|
2024
Q1 | $665K | Buy |
130,775
+17,091
| +15% | +$96.1K | ﹤0.01% | 2091 |
|
|
2023
Q4 | $681K | Buy |
113,684
+9,369
| +9% | +$54.3K | ﹤0.01% | 2038 |
|
|
2023
Q3 | $739K | Buy |
104,315
+8,473
| +9% | +$60.9K | ﹤0.01% | 1933 |
|
|
2023
Q2 | $675K | Buy |
95,842
+8,514
| +10% | +$68.3K | ﹤0.01% | 1994 |
|
|
2023
Q1 | $729K | Buy |
87,328
+3,504
| +4% | +$33.7K | ﹤0.01% | 1933 |
|
|
2022
Q4 | $962K | Buy |
83,824
+2,105
| +3% | +$26.3K | ﹤0.01% | 1790 |
|
|
2022
Q3 | $1.03M | Buy |
81,719
+5,573
| +7% | +$71.7K | ﹤0.01% | 1735 |
|
|
2022
Q2 | $806K | Sell |
76,146
-4,863
| -6% | -$50.2K | ﹤0.01% | 1989 |
|
|
2022
Q1 | $1.32M | Sell |
81,009
-6,836
| -8% | -$110K | ﹤0.01% | 1866 |
|
|
2021
Q4 | $1.22M | Sell |
87,845
-6,012
| -6% | -$79.6K | ﹤0.01% | 1929 |
|
|
2021
Q3 | $1.35M | Buy |
93,857
+1,691
| +2% | +$26.7K | ﹤0.01% | 1892 |
|
|
2021
Q2 | $1.46M | Sell |
92,166
-3,824
| -4% | -$52K | ﹤0.01% | 1880 |
|
|
2021
Q1 | $976K | Buy |
95,990
+8,645
| +10% | +$89.1K | ﹤0.01% | 2063 |
|
|
2020
Q4 | $651K | Buy |
87,345
+52,230
| +149% | +$269K | ﹤0.01% | 2124 |
|
|
2020
Q3 | $121K | Buy |
35,115
+24,005
| +216% | +$103K | ﹤0.01% | 2504 |
|
|
2020
Q2 | $53K | Buy |
11,110
+816
| +8% | +$3.26K | ﹤0.01% | 2460 |
|
|
2020
Q1 | $21K | Sell |
10,294
-2,635
| -20% | -$7.25K | ﹤0.01% | 2486 |
|
|
2019
Q4 | $45K | Buy |
+12,929
| New | +$32.5K | ﹤0.01% | 2497 |
|
|
2017
Q4 | – | Sell |
-27,923
| Closed | -$146K | – | 2569 |
|
|
2017
Q3 | $146K | Buy |
+27,923
| New | +$143K | ﹤0.01% | 2462 |
|
|
2016
Q1 | – | Sell |
-750,100
| Closed | -$7.74M | – | 2507 |
|
|
2015
Q4 | $7.74M | Sell |
750,100
-356,989
| -32% | -$3.55M | ﹤0.01% | 1331 |
|
|
2015
Q3 | $12.6M | Buy |
+1,107,089
| New | +$14.8M | ﹤0.01% | 1248 |
|
|
2014
Q4 | – | Sell |
-17,033
| Closed | -$167K | – | 2538 |
|
|
2014
Q3 | $167K | Buy |
+17,033
| New | +$209K | ﹤0.01% | 2385 |
|
|
2014
Q2 | – | Sell |
-1,583,000
| Closed | -$16.7M | – | 2532 |
|
|
2014
Q1 | $16.7M | Buy |
+1,583,000
| New | +$16.9M | ﹤0.01% | 1164 |
|
Other funds holding BCRX
RCM
DM
VPM
VCM
TCM
PA
VPC